

Special Issue

Molecular and Cellular Biology of Glioblastoma

Message from the Guest Editors

Glioblastoma, derived from glial and astrocytes, accounts for most brain tumors and is the most malignant in all kinds of brain tumors. The standard treatment for glioblastoma is temozolomide (TMZ)-mediated chemotherapy conjugated with radiotherapy (CCRT) after surgery. Unfortunately, the efficacy of CCRT is always restricted within a short period due to the high prevalence of tumor recurrence. A recurrent tumor always exhibits higher and higher tolerance in response to TMZ treatment cycle, leading to drug resistance, which is the main obstacle in improving patients' prognosis. In addition, the blood–brain barrier protects brain tissue, and protects brain tumors against chemotherapeutic drugs, further increasing the difficulty in drug discovery for glioblastoma. Therefore, we still have to make numerous efforts in dissecting important mechanisms and in investigating novel biomarkers underlying the acquirement of chemotherapeutic resistance by glioblastoma.

Guest Editors

Dr. Tsung-I Hsu

Ph.D. Program for Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan

Prof. Dr. Jian-Ying Chuang

Ph.D. Program for Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan

Deadline for manuscript submissions

closed (31 December 2021)



Life

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



mdpi.com/si/79762

Life

Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
life@mdpi.com

mdpi.com/journal/

[life](https://mdpi.com/journal/life)





Life

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
life](https://mdpi.com/journal/life)



About the Journal

Message from the Editor-in-Chief

Life (ISSN 2075-1729) is an international, peer-reviewed open access journal that publishes scientific studies related to fundamental themes in life sciences. Some papers are published individually, while others are submitted for inclusion in special issues with guest editors. You are invited to contribute a research article, essay, or a review to be considered for publication.

Editor-in-Chief

Prof. Dr. Lluís Ribas de Pouplana

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona
Institute of Science and Technology, 08028 Barcelona, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (Paleontology)